XBIOW | Xenetic Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	16.70 - 17.54
52 Week Range	1.0200 - 20.50
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2
Average Volume	635
Shares Outstanding	326,188
Market Cap	26,963,856
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-07-23

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIOW's peers: ZJZZT, VSSYW, ZXZZT

*Chart delayed

Analyzing fundamentals for XBIOW we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see XBIOW Fundamentals page.

Watching at XBIOW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XBIOW Technicals page.